Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half
Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing IVT injection patient discomfort.
Read original at benzingaStocks · News reference
Samsung Bioepis, Harrow Present SB11 Safety Data At ASRS 2026 Annual Meeting; Interim PMS Study Shows SB11 Comparable To Lucentis
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional and anatomical
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 12:04 PM
- Checked
- Jul 20, 2026, 12:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study
Read original at benzingaBTIG Reiterates Buy on Harrow, Maintains $63 Price Target
BTIG analyst Thomas Shrader reiterates Harrow (NASDAQ:HROW) with a Buy and maintains $63 price target.
Read original at benzingaOppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures mostly lower. OppFi (OPFI) shares fall after missing Q2 earnings and cutting FY26 guidance. Other stocks also down in pre-market.
Read original at benzinga